1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,050 | 8,350 | 28.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.01. | Elicio Therapeutics Inc.: Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy | 93 | GlobeNewswire (Europe) | Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis Phase 2 randomized study... ► Artikel lesen | |
| 22.01. | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.12.24 | Elicio reports promising cancer vaccine trial results | 1 | Investing.com | ||
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.12.24 | Elicio meldet vielversprechende Ergebnisse der Krebsimpfstoff-Studie | 8 | Investing.com Deutsch | ||
| 12.12.24 | Elicio Therapeutics Inc.: Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 | 105 | GlobeNewswire (Europe) | Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population Strong correlation observed between mRFS... ► Artikel lesen | |
| 12.12.24 | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.24 | Elicio completes phase 2 enrollment for cancer vaccine | 1 | Investing.com | ||
| 03.12.24 | Elicio schließt Patientenrekrutierung für Phase-2-Studie eines Krebsimpfstoffs ab | 1 | Investing.com Deutsch | ||
| 03.12.24 | Elicio Therapeutics Inc.: Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment | 87 | GlobeNewswire (Europe) | BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 03.12.24 | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.24 | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.24 | Elicio Therapeutics GAAP EPS of -$1.39 | 1 | Seeking Alpha | ||
| 13.11.24 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | 97 | GlobeNewswire (Europe) | AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival ("DFS") expected in H1 2025Poster presentation at the Society for... ► Artikel lesen | |
| 07.11.24 | Elicio reports promising Phase 1 cancer vaccine trial results | 1 | Investing.com | ||
| 07.11.24 | Elicio Therapeutics Inc.: Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting | 51 | GlobeNewswire (Europe) | Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens Correlation observed between disease-free survival... ► Artikel lesen | |
| 07.11.24 | Elicio Therapeutics adjourns annual meeting due to lack of quorum | 1 | Investing.com | ||
| 07.11.24 | Elicio Therapeutics vertagt Jahreshauptversammlung aufgrund fehlender Beschlussfähigkeit | - | Investing.com Deutsch | ||
| 07.11.24 | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.10.24 | Elicio Therapeutics Inc.: Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit | 1 | GlobeNewswire (USA) | ||
| 30.10.24 | Elicio Therapeutics stock rated Buy with $9 target by Jones Trading | 1 | Investing.com |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,415 | 0,00 % | Nanorepro: "Bedeutender Schritt für die Zukunft" | Nanorepro kommt 2024 auf einen Umsatz von 4,4 Millionen Euro (Vorjahr: 3,2 Millionen Euro). Mit Corona-Tests, dem Umsatztreiber in früheren Jahren, werden dabei nur noch marginale Umsätze erzielt. Vor... ► Artikel lesen | |
| OCUGEN | 0,692 | -0,93 % | Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 | OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clinical trial is anticipated to start in... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,250 | +4,23 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity | 13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily
SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking")... ► Artikel lesen | |
| SCORPIUS | 0,292 | +6,42 % | XFRA 1HB0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCORP.HLDGS.NEW... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,620 | +0,77 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,700 | +0,89 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) | -ORLADEYO net revenue expected to be between $515-$535 million in 2025- -Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025- -Company achieved operating profit in... ► Artikel lesen | |
| VAXART | 0,680 | -2,58 % | Vaxart beruft neues Vorstandsmitglied mit Gesundheitsexpertise | ||
| REDHILL BIOPHARMA | 6,110 | 0,00 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| IBIO | 2,910 | -0,51 % | iBio, Inc.: iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio | SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,210 | -1,71 % | Arbutus Biopharma (NASDAQ:ABUS) Receives "Buy" Rating from HC Wainwright | ||
| MANNKIND | 5,406 | -6,83 % | MannKind Reports Encouraging 6-month Data From Phase 3 INHALE-1 Study | WASHINGTON (dpa-AFX) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin... ► Artikel lesen | |
| ALDEYRA | 5,000 | +4,14 % | Aldeyra Therapeutics Aktie: Umsatzprognosen klar übertroffen! | Die Aldeyra Therapeutics Aktie verzeichnete am 23. November einen bemerkenswerten Handelstag mit einem Kursanstieg von 1,73 Prozent auf 4,70 EUR. Der Biotech-Konzern, der sich auf die Entwicklung von... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 3,320 | +2,15 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial | - Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control... ► Artikel lesen | |
| TRAWS PHARMA | 4,490 | -100,00 % | Traws Pharma, Inc.: Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu | Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention
NEWTOWN... ► Artikel lesen | |
| COHERUS | 1,032 | -7,11 % | Coherus BioSciences, Inc.: Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 | - Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate - - Antitumor... ► Artikel lesen |
Das Unternehmen ELICIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,500 (+6,54 %) liegt der Kurs bei 8,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.
